5-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenol | 1606168-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenol
• 英文别名: 5-[[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino]-2-methylphenol
• CAS: 1606168-13-1
• 化学式: C₁₈H₁₇N₃O₂
• 分子量: 307.352
• InChiKey: CJVAILQDNMMNII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  67.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenol 在 三甲基氯硅烷 、 potassium tert-butylate 、 potassium iodide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 20.5h， 生成 4-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}phenyl hydrogen propylphosphonate
  参考文献：
  名称：

  Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors

  摘要：

  Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

  DOI：

  10.1021/jm401742r
• 作为产物：
  描述：

  5-氨基-2-甲基苯酚 、 4-chloro-6-(2-methoxyphenyl)pyrimidine 在 盐酸 作用下， 以 水 、 异丙醇 为溶剂， 反应 1.0h， 以60%的产率得到5-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenol
  参考文献：
  名称：

  Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors

  摘要：

  Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.

  DOI：

  10.1021/jm401742r